Publications by authors named "Bernard G Combe"
Background: Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Filgotinib is a Janus kinase 1-preferential inhibitor available in two doses for moderate-to-severe RA. We report the long-term efficacy and safety of filgotinib.
View Article and Find Full Text PDFArticle Synopsis
- Filgotinib is an oral medication that effectively reduces the progression of rheumatoid arthritis (RA) in patients with inadequate response to methotrexate and shows a good safety profile compared to placebo and methotrexate alone.
- This review analyzes data from phase 3 trials focusing on patients with multiple poor prognostic factors (PPFs) and those at risk for rapid radiographic progression, suggesting that these factors could indicate higher disease risk.
- Ultimately, the findings aim to guide treatment decisions for patients with RA who are at an increased risk for joint damage due to radiographic progression.
Article Synopsis
- - This study investigated the effectiveness and safety of filgotinib (FIL) in rheumatoid arthritis patients who did not respond well to methotrexate and had four specific poor prognostic factors.
- - Patients were treated with either a placebo, FIL (200 mg or 100 mg), or adalimumab, and the analysis found that those on FIL showed significantly better responses in terms of disease activity at 12 weeks compared to placebo.
- - By 52 weeks, FIL200 not only maintained a greater response compared to adalimumab but also showed less progression in joint damage, with similar tolerability across all treatment groups.
Article Synopsis
- The study aimed to evaluate the safety and efficacy of filgotinib, a JAK1 preferential inhibitor, in Japanese patients who had an inadequate response to methotrexate (MTX) over 52 weeks.
- Patients were randomly assigned to receive either filgotinib or adalimumab while continuing stable doses of MTX, with efficacy assessed at various intervals and safety monitored through adverse event reporting.
- Results showed that filgotinib maintained efficacy and safety over the one-year period, with adverse events remaining consistent when compared to the overall population, indicating its potential as a viable treatment option.
Article Synopsis
- The study assessed the effectiveness and safety of filgotinib, a Janus kinase-1 inhibitor, in Japanese rheumatoid arthritis patients who didn't respond well to methotrexate.
- In a 52-week study of 147 patients, filgotinib showed higher American College of Rheumatology response rates and better disease control compared to adalimumab and placebo after 24 weeks.
- Treatment was generally safe, with low rates of serious infections and no deaths, indicating filgotinib's potential as a beneficial therapy for this patient group.
Objectives: To complete reporting of outcomes after total withdrawal of all rheumatoid arthritis (RA) therapy and re-treatment after flare in Assessing Very Early Rheumatoid arthritis Treatment study (NCT01142726).
Methods: Patients with early RA were initially randomised to double-blind, weekly subcutaneous abatacept plus methotrexate, or abatacept or methotrexate monotherapy. At month 12, patients with Disease Activity Score (DAS)28 C reactive protein (CRP) <3.
The article "On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis", written by Vivian P.Bykerk, was originally published Online First without open access.
View Article and Find Full Text PDFClinical outcomes in patients with early rheumatoid arthritis (RA) were assessed by baseline symptom duration in the Assessing Very Early Rheumatoid arthritis Treatment trial (ClinicalTrials.gov; NCT01142726). Patients with early, active RA were randomized to subcutaneous (SC) abatacept 125 mg/week plus methotrexate (MTX), SC abatacept alone, or MTX monotherapy for 12 months.
View Article and Find Full Text PDFObjectives: To assess structural damage progression with subcutaneous abatacept (ABA) in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial following abrupt withdrawal of all rheumatoid arthritis (RA) medication in patients achieving Disease Activity Score (DAS)-defined remission or low disease activity.
Methods: Patients with early, active RA were randomised to ABA plus methotrexate (ABA/MTX) 125 mg/week, ABA 125 mg/week or MTX for 12 months. All RA treatments were withdrawn after 12 months in patients with DAS28 (C reactive protein (CRP)) <3.
Objectives: To evaluate clinical remission with subcutaneous abatacept plus methotrexate (MTX) and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis (RA), and maintenance of remission following the rapid withdrawal of all RA treatment.
Methods: In the Assessing Very Early Rheumatoid arthritis Treatment phase 3b trial, patients with early active RA were randomised to double-blind, weekly, subcutaneous abatacept 125 mg plus MTX, abatacept 125 mg monotherapy, or MTX for 12 months. Patients with low disease activity (Disease Activity Score (DAS)28 (C reactive protein (CRP)) <3.